Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial

A DUPLEX sub-analysis found that sparsentan lowered protein in the urine and led to more complete remissions than irbesartan even in patients with genetic forms of FSGS — a group that usually resists treatment.